Measuring treatment effects of cilostazol on clinical trial endpoints in patients with intermittent claudication (Q34562427)

3 August 2017

1 reference

title

Measuring treatment effects of cilostazol on clinical trial endpoints in patients with intermittent claudication (English)

1 reference

3 August 2017

1 reference

James A M Smith

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6654755&resulttype=core&format=json

15 May 2020

language of work or name

1 reference

1 March 2002

1 reference

3 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6654755&resulttype=core&format=json

15 May 2020

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6654755&resulttype=core&format=json

15 May 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6654755&resulttype=core&format=json

15 May 2020

page(s)

91-94

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6654755&resulttype=core&format=json

The role of tobacco cessation, antiplatelet and lipid-lowering therapies in the treatment of peripheral arterial disease

15 May 2020

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FCLC.4960250303

Clinical trials for claudication. Assessment of exercise performance, functional status, and clinical end points. Vascular Clinical Trialists.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FCLC.4960250303

Update on Some Epidemiologic Features of Intermittent Claudication: The Framingham Study

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FCLC.4960250303

The effect of withdrawal of drugs treating intermittent claudication

21 January 2018

1 reference

12 December 2020

A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial

1 reference

12 December 2020

Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC).

1 reference

12 December 2020

Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease

1 reference

12 December 2020

Effect of hepatic impairment on the pharmacokinetics of a single dose of cilostazol

1 reference

12 December 2020

Effect of renal impairment on the pharmacokinetics of cilostazol and its metabolites

1 reference

12 December 2020

Effect of multiple cilostazol doses on single dose lovastatin pharmacokinetics in healthy volunteers

1 reference

12 December 2020

Effect of cilostazol on the pharmacokinetics and pharmacodynamics of warfarin

1 reference

12 December 2020

Interaction potential and tolerability of the coadministration of cilostazol and aspirin

1 reference

12 December 2020

1 reference

12 December 2020

Cilostazol, a selective type III phosphodiesterase inhibitor, decreases triglyceride and increases HDL cholesterol levels by increasing lipoprotein lipase activity in rats

1 reference

12 December 2020

A comparison of cilostazol and pentoxifylline for treating intermittent claudication

1 reference

12 December 2020

The Potential of Cilostazol in Interventional Cardiology

1 reference

12 December 2020

Effects of cilostazol on heart rate and its variation in patients with atrial fibrillation associated with bradycardia

1 reference

12 December 2020

[Research and development of cilostazol: an antiplatelet agent]

1 reference

12 December 2020

Cilostazol, a phosphodiesterase inhibitor, improves insulin sensitivity in the Otsuka Long-Evans Tokushima Fatty Rat, a model of spontaneous NIDDM.

1 reference

12 December 2020

Characteristics of heparin-induced platelet aggregates in chronic hemodialysis with long-term heparin use.

1 reference

12 December 2020

The localization of a new antithrombotic agent, cilostazol, in CHO-K1 cells as demonstrated by autoradiography.

1 reference

12 December 2020

Effect of cilostazol on platelet aggregation and experimental thrombosis

1 reference

12 December 2020

Hemodynamic effects of the antithrombotic drug cilostazol in chronic arterial occlusion in the extremities

1 reference

12 December 2020

Maximal oxygen intake and nomographic assessment of functional aerobic impairment in cardiovascular disease

1 reference

12 December 2020

Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study.

1 reference

12 December 2020

Exercise training improves functional status in patients with peripheral arterial disease

1 reference

12 December 2020

Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease

1 reference

12 December 2020

Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial

1 reference

12 December 2020

Antithrombotic therapy in peripheral arterial occlusive disease

1 reference

12 December 2020

Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication

1 reference

12 December 2020

Identifiers

DOI

10.1002/CLC.4960250303

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6654755&resulttype=core&format=json

15 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6654755&resulttype=core&format=json

15 May 2020

11892686

1 reference